BridgeBio Pharma, Inc. (MUN:2CL)
Germany · Delayed Price · Currency is EUR | Market Cap | 11.02B +81.6% |
| Revenue (ttm) | 503.00M +355.2% |
| Net Income | -625.80M |
| EPS | -3.25 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49 |
| Average Volume | 111 |
| Open | 57.99 |
| Previous Close | n/a |
| Day's Range | 54.60 - 57.99 |
| 52-Week Range | 33.42 - 64.84 |
| Beta | n/a |
| RSI | 61.24 |
| Earnings Date | May 7, 2026 |
About BridgeBio Pharma
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial numbers in USD Financial StatementsNews
BridgeBio Pharma Transcript: Bank of America Global Healthcare Conference 2026
Strong commercial momentum is driven by Attruby’s differentiation in efficacy, safety, and convenience, with robust pipeline launches expected to add significant revenue. Recent IP clarity and real-world data support confidence in achieving peak sales targets, while launch readiness is underpinned by experienced leadership and expanding patient identification efforts.
BridgeBio shares have ‘clear path’ to $90s, says JPMorgan
JPMorgan views BridgeBio (BBIO) as a top idea and sees a buying opportunity at current share levels. The stock closed Monday down 4% to $64.686. The firm sees a “clear…
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1
BridgeBio announces new data of Phase 3 ATTRibute-CM study at Heart Failure 2026
BridgeBio Pharma (BBIO) announced new data from the Phase 3 ATTRibute-CM study at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology, further demonstr...
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p
BridgeBio price target raised to $110 from $100 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $110 from $100 and keeps a Buy rating on the shares. The company reported solid revenue outperformance in Q1,…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condit...
BridgeBio price target raised to $130 from $125 at Evercore ISI
Evercore ISI raised the firm’s price target on BridgeBio (BBIO) to $130 from $125 and keeps an Outperform rating on the shares.
BridgeBio price target lowered to $94 from $98 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BridgeBio (BBIO) to $94 from $98 and keeps an Overweight rating on the shares.
BridgeBio price target raised to $114 from $100 at Bernstein
Bernstein raised the firm’s price target on BridgeBio (BBIO) to $114 from $100 and keeps an Outperform rating on the shares. The firm notes Attruby U.S. product sales of $181M…
BridgeBio files automatic mixed securities shelf
06:10 EDT BridgeBio (BBIO) files automatic mixed securities shelf
BridgeBio Pharma Earnings Call Transcript: Q1 2026
Q1 2026 delivered robust revenue growth, led by Attruby's blockbuster trajectory and expanding market share. Three major launches are on track, supported by strong clinical data and commercial readiness. A $500M share buyback was authorized, reflecting confidence in long-term value.
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develop...
BridgeBio receives regulatory approval in Brazil for Beyonttra
BridgeBio (BBIO) Pharma announced the Brazilian Health Regulatory Agency, ANVISA, has granted marketing authorization for acoramidis, under the brand name Beyonttra, for the treatment of wild-type or ...
BridgeBio to Participate in May and June Investor Conferences
PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condit...
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to ...
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condit...
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condit...
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic cond...
BridgeBio price target raised to $102 from $95 at Truist
Truist analyst Danielle Brill raised the firm’s price target on BridgeBio (BBIO) to $102 from $95 and keeps a Buy rating on the shares. The firm notes that the Vyndamax…
BofA ups BridgeBio price target, cites exclusivity ‘disappointment’ for pullback
BofA raised the firm’s price target on BridgeBio (BBIO) to $96 from $95 and keeps a Buy rating on the shares after Pfizer (PFE) announced settlement agreements with generic drug…
BridgeBio turns negative after Pfizer details tamidis settlement
BridgeBio (BBIO) shares after now down 2%, or $1.23, to $73.27 in morning trading. Pfizer (PFE) said its tafamidis settlements with generic drug manufacturers extend the effective U.S. patent expiry…
BridgeBio jumps 12% to $83.18 as Pfizer confirms tafamidis settlement
10:18 EDT BridgeBio (BBIO) jumps 12% to $83.18 as Pfizer (PFE) confirms tafamidis settlement
BridgeBio could trade to $90-$110 on Pfizer settlement, says Mizuho
Mizuho says the firm just learned that Hikma and Pfizer (PFE) settled their current tafamidis litigation. The firm believes a “major overhang” has been removed on BridgeBio (BBIO) shares. Mizuho…
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p